Novotech, the leading global full-service clinical Contract Research Organization (CRO) specializing in partnering with biotech companies to accelerate the development of advanced therapeutics, has unveiled its latest industry report, Gastric Cancer – Global Clinical Trial Landscape (2024).

This comprehensive report examines the evolving landscape of gastric cancer (GC) research, offering key insights into emerging trends that are expected to shape the future of clinical trials and drug development for the disease. It highlights the progress made in the understanding and treatment of GC, while showcasing promising therapeutic pipelines aimed at improving patient outcomes.

Key Insights from the Report Include:

1. Surge in Global Clinical Trials:

   • Since 2019, over 2,000 clinical trials have been launched globally, with the Asia-Pacific region accounting for 52% of trials. Mainland China leads the region, with 48% of its trials dedicated to GC research. North America and Europe contribute 29% and 15% of global trials, respectively.

2. Innovative Drug Development:

   • The report identifies 228 drugs in various stages of development, focusing heavily on targeted therapies and immunotherapies. Of these, 11 drugs have already received approval, and 28 are on the market, underscoring significant advancements in treatment options.

3. Advanced Therapeutic Strategies:

   • Personalized medicine is at the forefront of GC treatment, with increasing focus on biomarker-directed therapies. Perioperative chemotherapy remains standard for resectable GC, but research is progressing toward combining targeted therapies with immunotherapies for enhanced treatment outcomes.

4. Significant Funding in GC Research:

   • From 2019 to 2023, GC research attracted $7.4 billion in venture capital funding globally. China led the way with $4.53 billion, followed by the United States with $2.97 billion.

5. Opportunities and Challenges:

   • The report highlights challenges such as high treatment costs and the need for improved patient selection for therapies. However, opportunities in liquid biopsies and molecular profiling for personalized treatments continue to grow.

Strategic Insights & Market Leaders: Key industry players such as Pfizer, Roche, Merck & Co., Eli Lilly, and Sanofi are identified as leaders in the GC treatment landscape. The report includes a comprehensive SWOT analysis, exploring the effectiveness of current treatments while identifying areas for future improvement through innovative techniques.

Shawn McCarthy, CEO of Novotech, commented, "This report reflects our ongoing commitment to supporting global biotech companies in driving advancements in gastric cancer treatments. The insights provided will help guide future research, enabling better treatment options for patients worldwide."

Novotech’s Gastric Cancer – Global Clinical Trial Landscape (2024) report is part of a series of expert reports released monthly, providing the latest updates on clinical trial landscapes, emerging therapies, and key trends in the biotech industry.

Gastric Cancer- Global Clinical Trial Landscape (2024) | Novotech CRO (novotech-cro.com)